OVID
Ovid Therapeutics Inc.
$2.61
-0.08 (-2.97%)
At close · Jul 6
Market Cap
$487.13M
Shares
186,640,102
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.61
Open$2.77
Day$2.60–2.77
52W$0.33–3.11
Avg vol 30d3.0M
Short int11.9M · 6.4% float · 6.7d
Short vol63%
Last earningsMar 18, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+34% above
+
Price vs 50-day avg
+2% above
◦
RSI (14)
55 · neutral
+
MACD trend
positive
◦
52-week position
82% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $3 › 200d $2 — 50d above 200d
+
Institutional flow
+23% holders QoQ · +30 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
6.35% of float · ▲ +11.5% MoM · 6.7 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
103 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+1181% Y/Y
◦
EPS growth
+4% Y/Y
−
Free cash flow
$-38.3M
+
Balance sheet
net cash $13.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 20, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+34% above
Bullish
Price vs 50-day avg
+2% above
Bullish
RSI (14)
55 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
82% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.35% of float · ▲ +11.5% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
103 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $3 · 82%
52-wk high $3
vs 200-day avg +34%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OVID
this stock
Ovid Therapeutics Inc.
|
$487.13M | +60.1% | +1181.3% | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.87B | +9.0% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OVID | +2.4% | +5.2% | +56.3% | -3.0% | +60.1% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -0.7% | +6.0% | +48.1% | -3.6% | +50.0% |